Promising opportunities to prevent the appearance and progression of liver fibrosis

April 27, 2021
1034
Resume

The pathophysiological mechanisms of liver fibrosis are considered in the article. It is noted that liver fibrosis is a sign of progression of chronic diffuse liver disease, its slowing down and regression is the goal of hepatoprotective therapeutic interventions. Effective etiotropic therapy, individual diet therapy and the use of optimal hepatoprotectors can prevent the appearance and progression of liver fibrosis. The basic principles of hepatoprotective therapy and characteristics of hepatoprotective drugs are given. An innovative complex of amino acid derivatives with hepatoprotective properties Livodinol® is presented, which allows to achieve a therapeutic goal in various chronic diffuse liver diseases.

References:

  • 1. Friedman S.L. (2010) Evolving challenges in hepatic fibrosis. Nat. Rev. Gastroenterol. Hepatol., 7: 425.
  • 2. Ismair M.G., Stieger B., Cattori V. et al. (2001) Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterol., 121: 1185.
  • 3. Friedman S.L. (2008) Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev., 88: 125.
  • 4. Marcellin P., Gane E., Buti M. et al. (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet, 381: 468.
  • 5. WHO (2020) WHO guidelines on physical activity and sedentary behaviour. Geneva.
  • 6. WHO (2018) Global status report on alcohol and health 2018. Geneva.
  • 7. Zelber-Sagi S., Salomone F., Mlynarsky L. (2017) The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int., 37(7): 936–949. doi: 10.1111/liv.13435
  • 8. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64(6): 1388–1402. doi: 10.1016/j.jhep.2015.11.004
  • 9. Alter M.J. (2012) Vaccinating patients with chronic liver disease. Gastroenterol. Hepatol. (N.Y.), 8(2): 120–122.
  • 10. Friedman S.L., Sheppard D., Duffield J.S., Violette S. (2013) Therapy for fibrotic diseases: nearing the starting line. Sci. Transl. Med., 5: 167sr1.
  • 11. Lee Y.A., Friedman S.L. (2014) Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral. Res., 107: 23.
  • 12. Klein S., Mittendorfer B., Eagon J.C. et al. (2006) Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology, 130: 1564.
  • 13. Khalaf N., White D., Kanwal F. et al. (2015) Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C. Clin. Gastroenterol. Hepatol., 13: 1521.
  • 14. Melhem A., Muhanna N., Bishara A. et al. (2006) Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J. Hepatol., 45: 60.
  • 15. Jeong W.I., Park O., Gao B. (2008) Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology, 134: 248.
  • 16. Sanyal A.J., Chalasani N., Kowdley K.V. et al. (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med., 362: 1675.
  • 17. Trappoliere M., Caligiuri A., Schmid M. et al. (2009) Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J. Hepatol., 50: 1102.